<DOC>
	<DOCNO>NCT01578109</DOCNO>
	<brief_summary>This pilot clinical trial study side effect sorafenib tosylate donor bone marrow transplantation treat patient acute myeloid leukemia . Sorafenib tosylate may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Sorafenib Tosylate Before After Donor Bone Marrow Transplant Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine toxicity safety incorporation sorafenib tosylate ( sorafenib ) pre- post-transplant maintenance set three type transplant . SECONDARY OBJECTIVES : I . Improvement 2 year disease free survival bone marrow transplant 25 % base baseline relapse free survival two year 30 % . II . Secondary graft failure define decline neutrophil count &lt; 500/cu mm achieve engraftment unrelated infection drug effect ( sorafenib ? ) unresponsive stimulation growth factor . III . Non-relapse mortality ( NRM ) define , death absence compete risk , relapse progression disease . IV . Survival without relapse death ( disease-free survival [ DFS ] ) without death ( overall survival [ OS ] ) determine present Kaplan-Meier estimate 1 2 year post-transplant . V. Patients evaluate chronic graft versus host disease ( GVHD ) describe National Institutes Health ( NIH ) consensus project guideline conventional criterion . TERTIARY OBJECTIVES : I . Patients undergo serial examination bone marrow maintenance treatment evaluate minimal residual disease ( MRD ) flow cytometry fms-related tyrosine kinase 3 ( FLT3 ) suppression western blot analysis plasma inhibitory assay ( PIA ) . OUTLINE : This dose-escalation study . Patients receive sorafenib tosylate orally ( PO ) twice daily ( BID ) begin least 30 day completion induction therapy and/or transplant 120 day transplant continue 2 year transplant absence disease progression unacceptable toxicity . After completion study treatment , patient follow 24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Acute myeloid leukemia fmslike tyrosine kinase 3 ( FLT3 ) internal tandem duplication ( ITD ) complete remission partial remission ( le 10 % blast marrow ) document bone marrow biopsy plan undergo bone marrow transplantation Patients count recovery ( absolute neutrophil count [ ANC ] &gt; 500,000/mm^3 ; non transfuse platelet count 30,000/mm^3 ) least 30 day induction and/or transplantation 120 day post transplant Patients may receive prior therapy deem necessary induction remission except patient progressed sorafenib ; patient respond sorafenib previously eligible enrollment protocol Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy great four month Total bilirubin le 2 x upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 5 x institutional upper limit normal Creatinine = &lt; 1.5 x upper limit normal OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level &gt; 1.5 x upper limit normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; contraception continue least 30 day last dose sorafenib Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 2 week except intrathecal chemotherapy ( i.e. , methotrexate , cytarabine , thiotepa ) Patients may receive investigational agent Patients uncontrolled hypertension ( i.e. , persistent grade 3 undergoing treatment ) History allergic reaction attribute compound similar chemical biologic composition sorafenib Patients active and/or untreated central nervous system ( CNS ) leukemia eligible Patients must evidence bleed diathesis therapeutic anticoagulation low molecular weight ( LMW ) heparin warfarin deep vein thrombosis ( DVT ) treatment Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated sorafenib Human immunodeficiency virus ( HIV ) positive patient exclude Patients active acute GVHD initiate therapy therapy escalation within 21 day eligible Patients lack engraftment ( less 90 % donor deoxyribonucleic acid [ DNA ] bone marrow peripheral blood ) bone marrow transplant evidence RFLP ( restriction fragment length polymorphism ) eligible Patients unable swallow pill eligible Patients take strong cytochrome P450 family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor include enzymeinducing antiepileptic drug ( phenytoin , carbazepine , phenobarbitol ) , rifampin , grape fruit juice , St. John 's wort eligible</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>